The DOI matches its Crossref record.
The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis
Open accessAbstract
// Min Yu 1, * , Han Yongzhi 2, * , Shengying Chen 1, * , Xiaodan Luo 3 , Ye Lin 1 , Yu Zhou 1 , Haosheng Jin 1 , Baohua Hou 1 , Yanying Deng 1 , Lei Tu 1 and Zhixiang Jian 1 1 Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China 2 Department of Dermatology, Guangdong General Hospital, Guangdong Academy of Medical Science, Guangzhou, China 3 Department of Infectious Diseases, Guangdong General Hospital, Guangdong Academy of Medical Science, Guangzhou, China * These authors contributed equally to this work Correspondence to: Min Yu, email: yuminzhongda@163.com Keywords: glucose transporter 1, prognostic marker, survival, cancer, glycolysis Received: July 18, 2016 Accepted: April 06, 2017 Published: April 27, 2017 ABSTRACT Increased glycolysis is one of the hallmarks of cancer. The abnormal expression of glucose transporter 1 (GLUT1) was reported to be associated with resistance to current therapy and poor prognosis. Numerous studies have investigated the correlation between GLUT1 expression and prognosis in cancers, but the conclusions are still controversial. Here, we conducted a meta-analysis to explore the association between GLUT1 and survival in human cancers. PubMed, Springer, Medline, and Cochrane Library were searched carefully to identify eligible studies evaluating prognostic value of GLUT1 in cancers. Twenty-seven studies with 4079 patients were included in the present study. Our pooled results identified that increased expression of GLUT1 was associated with unfavorable overall survival (HR = 1.780, 95% CI = 1.574–.013, p < 0.001)) and poorer disease-free survival (HR = 1.95, 95% CI = 1.229–3.095, p = 0.003). Furthermore, overexpression of GLUT1 linked with poor differentiated tumors (RR = 1.380, 95% CI = 1.086–1.755, p = 0.009; I 2 = 72.0%, p < 0.001), positive lymph node metastasis (RR = 1.395, 95% CI = 1.082–1.799, p = 0.010; I 2 = 70.8%, p = 0.002) and larger tumor size (RR = 1.405, 95% CI = 1.231–1.603, p < 0.001; I 2 = 37.3%, p = 0.093). This systematic review and meta-analysis indicated that the GLUT1 may serve as an ideal prognostic biomarker in various cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A guide to plasma membrane solute carrier proteins
Pizzagalli, M. D., Bensimon, A., & Superti‐Furga, G. (2021) · The FEBS Journal · doi:10.1111/febs.15531 · Cited by 379
HIFs, angiogenesis, and metabolism: Elusive enemies in breast cancer
de Heer, E. C., Jalving, M., & Harris, A. L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137552 · Cited by 372
EMT Factors and Metabolic Pathways in Cancer
Georgakopoulos-Soares, I., Chartoumpekis, D. V., Kyriazopoulou, V., & Zaravinos, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00499 · Cited by 349
The mechanism of Warburg effect-induced chemoresistance in cancer
Liu, C., Jin, Y., & Fan, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698023 · Cited by 177
Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression
Wang, K., Dai, X., Yu, A., Feng, C., Liu, K., & Huang, L. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02483-2 · Cited by 115
Metadata
- Authors
- Yu, M., Yongzhi, H., Chen, S., Luo, X., Lin, Y., Zhou, Y., Jin, H., Hou, B., Deng, Y., Tu, L., & Jian, Z.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-04-27
- Volume
- 8
- Issue
- 26
- Pages
- 43356-43367
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2607721315
- Cited by
- 166
- References
- 0
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.18632/oncotarget.17445
- The paper
- Yu, M., Yongzhi, H., Chen, S., Luo, X., Lin, Y., Zhou, Y., Jin, H., Hou, B., Deng, Y., Tu, L., & Jian, Z. (2017). The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis. Oncotarget. https://doi.org/10.18632/oncotarget.17445
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.